Centrifugal-flow ventricular assist device support in children: A single-center experience.
Adolescent
Age Factors
Cardiomyopathies
/ diagnostic imaging
Child
Child, Preschool
Device Removal
Female
Heart Defects, Congenital
/ diagnostic imaging
Heart-Assist Devices
Humans
Male
Prospective Studies
Prosthesis Design
Prosthesis Implantation
/ adverse effects
Recovery of Function
Texas
Time Factors
Treatment Outcome
Ventricular Function, Left
heart failure
mechanical circulatory support
outcomes
Journal
The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
18
05
2018
revised:
28
11
2018
accepted:
13
12
2018
pubmed:
17
2
2019
medline:
25
2
2020
entrez:
17
2
2019
Statut:
ppublish
Résumé
Our institutional policy is to continue centrifugal-flow ventricular assist device support for 3 months or more without activation on the transplant wait-list for physical recovery and assessment of possible myocardial recovery. We evaluated our single-institutional outcomes with centrifugal-flow ventricular assist device support in children. Prospectively collected outcomes data in consecutive patients aged 18 years or less with centrifugal-flow ventricular assist device support were reviewed. There were 40 implantations in 39 patients (28 with cardiomyopathy, 11 with congenital heart disease, including 3 with univentricular physiology). The median support was 8 months (range, 1-79), with 13 patients (33%) supported for 12 months or more and a cumulative duration of 41 patient-years. The median age and weight at implantation were 11 (4-18) years and 35 (14-98) kg, respectively. The median body surface area was 1.1 (0.7-2.2) m This study demonstrates favorable outcomes of centrifugal-flow ventricular assist device support in children, including those with congenital heart disease, with an increased incidence of cardiac recovery.
Sections du résumé
BACKGROUND
Our institutional policy is to continue centrifugal-flow ventricular assist device support for 3 months or more without activation on the transplant wait-list for physical recovery and assessment of possible myocardial recovery. We evaluated our single-institutional outcomes with centrifugal-flow ventricular assist device support in children.
METHODS
Prospectively collected outcomes data in consecutive patients aged 18 years or less with centrifugal-flow ventricular assist device support were reviewed.
RESULTS
There were 40 implantations in 39 patients (28 with cardiomyopathy, 11 with congenital heart disease, including 3 with univentricular physiology). The median support was 8 months (range, 1-79), with 13 patients (33%) supported for 12 months or more and a cumulative duration of 41 patient-years. The median age and weight at implantation were 11 (4-18) years and 35 (14-98) kg, respectively. The median body surface area was 1.1 (0.7-2.2) m
CONCLUSIONS
This study demonstrates favorable outcomes of centrifugal-flow ventricular assist device support in children, including those with congenital heart disease, with an increased incidence of cardiac recovery.
Identifiants
pubmed: 30770106
pii: S0022-5223(18)33484-6
doi: 10.1016/j.jtcvs.2018.12.045
pii:
doi:
Types de publication
Journal Article
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
1609-1617.e2Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2018 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.